Atlas Trials

An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

Clinical trial NCT02937168 · TERMINATED

Trial details

NCT number
NCT02937168
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Status
TERMINATED
Phase
Phase 4
Study type
INTERVENTIONAL
Asthma
Start date
2017-05-08
Primary completion
2017-05-24
Enrollment
5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.